Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses

International Journal of Molecular Sciences

Barbara Muoio¹  Giorgio Treglia²  Luca Giovanella²  MariaVittoria Mattoli³  Domenico Albano⁴  Francesco Bertagna⁴  Gianluca Trevisi⁵ 

[1] Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, CH-6500 Bellinzona, Switzerland;Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, CH-6500 Bellinzona, Switzerland;Department of Neurosciences, Imaging and Clinical Sciences, “G. D’Annunzio” University, IT-66100 Chieti, Italy;Department of Nuclear Medicine, Spedali Civili of Brescia and University of Brescia, IT-25123 Brescia, Italy;Neurosurgical Unit, Presidio Ospedaliero Santo Spirito, IT-65124 Pescara, Italy;

关键词: PET;    positron emission tomography;    brain tumors;    glioma;    brain metastases;    diagnostic performance;    prognosis;    meta-analysis;   

DOI  :  10.3390/ijms20194669

来源: DOAJ

【 摘 要 】

Background: Several meta-analyses reporting data on the diagnostic performance or prognostic value of positron emission tomography (PET) with different tracers in detecting brain tumors have been published so far. This review article was written to summarize the evidence-based data in these settings. Methods: We have performed a comprehensive literature search of meta-analyses published in the Cochrane library and PubMed/Medline databases (from inception through July 2019) about the diagnostic performance or prognostic value of PET with different tracers in patients with brain tumors. Results: We have summarized the results of 24 retrieved meta-analyses on the use of PET or PET/computed tomography (CT) with different tracers in brain tumors. The tracers included were: fluorine-18 fluorodeoxyglucose (¹⁸F-FDG), carbon-11 methionine (¹¹C-methionine), fluorine-18 fluoroethyltyrosine (¹⁸F-FET), fluorine-18 dihydroxyphenylalanine (¹⁸F-FDOPA), fluorine-18 fluorothymidine (¹⁸F-FLT), and carbon-11 choline (¹¹C-choline). Evidence-based data demonstrated good diagnostic performance of PET with different tracers in detecting brain tumors, in particular, radiolabelled amino acid tracers showed the highest diagnostic performance values. All the PET tracers evaluated had significant prognostic value in patients with glioma. Conclusions: Evidence-based data showed a good diagnostic performance for some PET tracers in specific indications and significant prognostic value in brain tumors.

【 授权许可】

Unknown